Colchicine comes from a plant called Colchicum autumnale, or autumn crocus, which is a member of the lily family.1 Plant extracts containing colchicine have been used to prevent gout flares for more than 2,000 years.1 West-Ward Pharmaceuticals (now known as Hikma Pharmaceuticals USA Inc.) received FDA approval for Mitigare® (Colchicine) 0.6 mg Capsules in 2014.
Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare® for acute treatment of gout flares during prophylaxis has not been studied. Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.
History of Mitigare®
The U.S. Food and Drug Administration (FDA) announced a new initiative to promote testing of medicines in use prior to the agency’s existence. Despite the fact that colchicine had been used to prevent gout flares for hundreds of years, unapproved formulations of the drug were banned a few years later.
The FDA approved Colcrys® (colchicine, USP) 0.6 mg tablet, which launched at a significantly higher price than pre-existing unapproved colchicine generics.
Colcrys® gained exclusivity in 2010 and began raising the price on Colchicine. Patients were forced to pay a premium price for Colcrys®, the only FDA-approved colchicine product at that time.
The FDA approved Mitigare® (Colchicine) 0.6 mg Capsules, the first and only other branded colchicine product for prevention of gout flares in adults.
Mitigare® and Authorized Generic Colchicine Capsules launch, generating competition and creating a possibility for people with gout to save on colchicine treatment for prevention of gout flares.
Hikma Pharmaceuticals USA Inc. launches Colchicine.com to offer information about Authorized Generic Colchicine Capsules.
2020 and beyond
Hikma Pharmaceuticals USA Inc. continues to provide Mitigare® and Authorized Generic Colchicine Capsules as affordable options to help adults prevent gout flares.